ANSTO LifeSciences, Australian Nuclear Science and Technology Organisation, Locked Bag 2001 Kirrawee DC, NSW 2232, Australia.
Anticancer Res. 2011 Sep;31(9):2883-8.
This study investigated the potential of a series of biomarkers in predicting the interaction of gefitinib and radiation in tumour treatment.
In vitro assays were performed on human skin cancer and melanoma cell lines. The antitumour effect was measured by using the MTT assay. Total and phosphorylated epidermal growth factor receptor (EGFR and pEGFR) levels were determined by cell-based ELISA.
Gefitinib and radiation interacted to inhibit tumour cell proliferation in a cell line-dependent manner. Synergism dominated the interaction (76%), followed by additive effect (20%) and a few instances of antagonism (4%). Correlation analyses revealed a significant correlation between the median combination index (CI) and gefitinib IC₅₀, radiation ID₅₀, gefitinib- or EGF-modulated EGFR and/or pEGFR expression (all p ≤ 0.05).
A potential role of gefitinib efficacy, radiation efficacy and gefitinib- or EGF-modulated EGFR and/or pEGFR expression in the prediction of interaction between gefitinib and radiation is supported.
本研究旨在探讨一系列生物标志物在预测吉非替尼与放疗相互作用中的潜力，以用于肿瘤治疗。
在体外培养的人类皮肤癌和黑色素瘤细胞系中进行了实验。采用 MTT 法测定抗肿瘤作用。通过基于细胞的 ELISA 法测定总表皮生长因子受体（EGFR 和 pEGFR）和磷酸化 EGFR（pEGFR）的水平。
吉非替尼和放疗以细胞系依赖性方式相互作用抑制肿瘤细胞增殖，以协同作用（76%）为主，相加作用（20%）次之，拮抗作用较少（4%）。相关性分析显示，中位联合指数（CI）与吉非替尼 IC₅₀、放疗 ID₅₀、吉非替尼或 EGF 调节的 EGFR 和/或 pEGFR 表达之间存在显著相关性（均 p≤0.05）。
吉非替尼疗效、放疗疗效以及吉非替尼或 EGF 调节的 EGFR 和/或 pEGFR 表达在预测吉非替尼与放疗相互作用中的作用具有潜在意义。
